Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology
- Author
- GAZARIAN, M1 2 ; TUGWELL, P3 ; BOERS, M4 ; BOMBARDIER, C5 ; BROOKS, P6 ; DAY, R7 ; STRAND, V8 ; WELLS, G9
[1] School of Paediatrics, University of New South Wales and Sydney Children's Hospital, Sydney, Australia
[2] School of Physiology and Pharmacology. University of New South Wales, Sydney, Australia
[3] Department of Medicine, University of Ottawa, Ottawa, Canada
[4] Department of Clinical Epidemiology, Free University, Amsterdam, Netherlands
[5] Wellesley Hospital Research Institute and the University of Toronto, Toronto, Canada
[6] University of Queensland, Royal Brisbane Hospital, Herston, Sydney, Australia
[7] St. Vincent's Hospital and University of New South Wales, Sydney, Australia
[8] Clinical Faculty Stanford University, San Francisco, United States
[9] Clinical Epidemiology Unit, University of Ottawa, Canada - Conference title
- Outcome measures in rheumatology
- Conference name
- OMERACT IV: International Consensus Conference (4 ; Cancun 1998-04-16)
- Author (monograph)
- Outcome MEasures in Rheumatoid Arthritis Clinical Trials (Funder/Sponsor)
- Source
Journal of rheumatology. 1999, Vol 26, Num 1, pp 207-209 ; ref : 13 ref
- CODEN
- JRHUA9
- ISSN
- 0315-162X
- Scientific domain
- Rheumatology
- Publisher
- Journal of Rheumatology Publishing, Toronto, ON
- Publication country
- Canada
- Document type
- Conference Paper
- Language
- English
- Keyword (fr)
- Commission Essai clinique Evaluation Homme Méthodologie Pharmacovigilance Pronostic Rhumatologie Toxicité Traitement Outcome Measures in Rheumatoid Arthritis Clinical Trials
- Keyword (en)
- Commission Clinical trial Evaluation Human Methodology Pharmacovigilance Prognosis Rheumatology Toxicity Treatment
- Keyword (es)
- Comisión Ensayo clínico Evaluación Hombre Metodología Farmacovigilancia Pronóstico Reumatología Toxicidad Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02A General pharmacology / 002B02A06 Clinical trial. Drug monitoring
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 1652720
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Journal of rheumatology\";s:9:\"\u0000*\u0000stitle\";s:12:\"J. rheumatol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"207\";s:8:\"\u0000*\u0000epage\";s:3:\"209\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0315-162X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GAZARIAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:10:\"TUGWELL, P\";i:1;s:8:\"BOERS, M\";i:2;s:13:\"BOMBARDIER, C\";i:3;s:9:\"BROOKS, P\";i:4;s:6:\"DAY, R\";i:5;s:9:\"STRAND, V\";i:6;s:8:\"WELLS, G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JRHUA9\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:32:\"Outcome measures in rheumatology\";s:8:\"\u0000*\u0000title\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:8:\"\u0000*\u0000place\";s:11:\"Toronto, ON\";s:6:\"\u0000*\u0000pub\";s:34:\"Journal of Rheumatology Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Journal of rheumatology\";s:9:\"\u0000*\u0000stitle\";s:12:\"J. rheumatol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"207\";s:8:\"\u0000*\u0000epage\";s:3:\"209\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0315-162X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GAZARIAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:10:\"TUGWELL, P\";i:1;s:8:\"BOERS, M\";i:2;s:13:\"BOMBARDIER, C\";i:3;s:9:\"BROOKS, P\";i:4;s:6:\"DAY, R\";i:5;s:9:\"STRAND, V\";i:6;s:8:\"WELLS, G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JRHUA9\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:32:\"Outcome measures in rheumatology\";s:8:\"\u0000*\u0000title\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:8:\"\u0000*\u0000place\";s:11:\"Toronto, ON\";s:6:\"\u0000*\u0000pub\";s:34:\"Journal of Rheumatology Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Journal of rheumatology\";s:9:\"\u0000*\u0000stitle\";s:12:\"J. rheumatol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"207\";s:8:\"\u0000*\u0000epage\";s:3:\"209\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0315-162X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GAZARIAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:10:\"TUGWELL, P\";i:1;s:8:\"BOERS, M\";i:2;s:13:\"BOMBARDIER, C\";i:3;s:9:\"BROOKS, P\";i:4;s:6:\"DAY, R\";i:5;s:9:\"STRAND, V\";i:6;s:8:\"WELLS, G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JRHUA9\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:32:\"Outcome measures in rheumatology\";s:8:\"\u0000*\u0000title\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:8:\"\u0000*\u0000place\";s:11:\"Toronto, ON\";s:6:\"\u0000*\u0000pub\";s:34:\"Journal of Rheumatology Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Journal of rheumatology\";s:9:\"\u0000*\u0000stitle\";s:12:\"J. rheumatol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"207\";s:8:\"\u0000*\u0000epage\";s:3:\"209\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0315-162X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GAZARIAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:10:\"TUGWELL, P\";i:1;s:8:\"BOERS, M\";i:2;s:13:\"BOMBARDIER, C\";i:3;s:9:\"BROOKS, P\";i:4;s:6:\"DAY, R\";i:5;s:9:\"STRAND, V\";i:6;s:8:\"WELLS, G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JRHUA9\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:32:\"Outcome measures in rheumatology\";s:8:\"\u0000*\u0000title\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:8:\"\u0000*\u0000place\";s:11:\"Toronto, ON\";s:6:\"\u0000*\u0000pub\";s:34:\"Journal of Rheumatology Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Journal of rheumatology\";s:9:\"\u0000*\u0000stitle\";s:12:\"J. rheumatol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"207\";s:8:\"\u0000*\u0000epage\";s:3:\"209\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0315-162X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"GAZARIAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:10:\"TUGWELL, P\";i:1;s:8:\"BOERS, M\";i:2;s:13:\"BOMBARDIER, C\";i:3;s:9:\"BROOKS, P\";i:4;s:6:\"DAY, R\";i:5;s:9:\"STRAND, V\";i:6;s:8:\"WELLS, G\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JRHUA9\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:32:\"Outcome measures in rheumatology\";s:8:\"\u0000*\u0000title\";s:181:\"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working party : Outcome Measures in Rheumatology\";s:8:\"\u0000*\u0000place\";s:11:\"Toronto, ON\";s:6:\"\u0000*\u0000pub\";s:34:\"Journal of Rheumatology Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
